TP53 and cancer: Since p53 function is lost in over 50% of tumors, and both DDIT3 and TIGAR mutations are comparatively rare,[54] this suggests that the DDIT3‐TIGAR‐glycolytic axis would remain intact in the majority of cancer cells.